Westover Capital Advisors LLC Has $1.42 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Westover Capital Advisors LLC cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,576 shares of the biopharmaceutical company’s stock after selling 942 shares during the quarter. Westover Capital Advisors LLC owned about 0.07% of Catalyst Pharmaceuticals worth $1,422,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CPRX. Jupiter Asset Management Ltd. increased its holdings in shares of Catalyst Pharmaceuticals by 64.0% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 897,046 shares of the biopharmaceutical company’s stock worth $10,486,000 after acquiring an additional 350,184 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Catalyst Pharmaceuticals by 110.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 636,366 shares of the biopharmaceutical company’s stock valued at $7,439,000 after buying an additional 333,562 shares in the last quarter. LSV Asset Management grew its holdings in Catalyst Pharmaceuticals by 25.6% in the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock valued at $14,505,000 after buying an additional 253,100 shares in the last quarter. Clark Estates Inc. NY acquired a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $2,198,000. Finally, Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 7,046,487 shares of the biopharmaceutical company’s stock valued at $82,373,000 after buying an additional 174,739 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the company. Bank of America assumed coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Oppenheimer reissued an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a report on Wednesday, March 27th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Stock Down 1.1 %

Catalyst Pharmaceuticals stock traded down $0.17 during trading hours on Thursday, hitting $15.03. The stock had a trading volume of 481,600 shares, compared to its average volume of 1,439,936. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 24.69, a P/E/G ratio of 0.83 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a one year low of $11.09 and a one year high of $17.76. The business’s 50 day simple moving average is $15.62 and its 200-day simple moving average is $14.68.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. Research analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current fiscal year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the transaction, the insider now directly owns 124,433 shares in the company, valued at $2,045,678.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.